Vitiligo From Checkpoint Inhibitors Not Limited to Melanoma
Vitiligo induced by immune checkpoint inhibitors (ICIs) can occur in virtually any type of cancer. The finding challenges the notion that ICI-induced vitiligo is limited to melanoma patients. With growing use of checkpoint inhibitors for nonmelanoma cancers, the diversity of patients' skin color is expected to increase, leading to a greater impact of vitiligo on quality of life and importance of vitiligo-related outcomes.
@digambar Vitiligo reporting was often inconsistent, with skipped chart notes and nonspecific descriptions. It's unknown if vitiligo is associated with good outcomes in cancers other than melanoma.